Trials
2 active
11 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intravenous solution of AZD4144 will be administered to randomised participants according to the treatment arm to which they have been assigned.”In the company’s words, NCT07215702 on ClinicalTrials.gov
- Tested for
- Sepsis, Acute Kidney Injury, Hepatic Impairment
- Main trialPhase 2
- “This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period,…”In the company’s words, NCT07215702 on ClinicalTrials.gov
Other drugs for Sepsis
- Meropenem and PralurbactamQilu Pharmaceutical · Phase 3
- FosmanogepixBasilea Pharmaceutica · Phase 3
- YD0743Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Phase 2
- AZD7760AstraZeneca · Phase 1/2
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2
- ARTICEArtcline GmbH · Phase 2
Coming up2
- 11 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 28 May 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 11 Feb 2027 | A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | |
| Phase 1Not yet recruiting | 28 May 2027 | A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144 | |
| Phase 1Completed | 4 Dec 2024 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants | |
| Phase 1Completed | 23 Apr 2025 | A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants | |
| Phase 1Completed | 11 Jun 2025 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants | |
| Phase 1Completed | 12 Jun 2025 | A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants | |
| Phase 1Completed | 27 Jun 2025 | A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants | |
| Phase 1Completed | 29 Sep 2025 | A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity | |
| Phase 1Completed | 27 Oct 2025 | A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. | |
| Phase 1Completed | 26 May 2026 | A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144 | |
| Phase 1Completed | 22 Oct 2026 | Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026